Molecular Pathology

Molecular genetic analysis of tissue samples has been developed in recent years become an indispensable part of modern pathology. It helps in making accurate diagnoses , and is also the basis of an increasingly personalized medicine , with an individualized therapy in increasing cancer. Even with various infectious diseases , the molecular pathology enables the detection of the specific pathogen.

The polymerase chain reaction (PCR ) and subsequent sequencing ( Sanger / Pyro ) , changes are identified in specific genes that allow the use of targeted drugs. By the use of specific DNA probes in fluorescent in situ hybridization (FISH) , tumor-specific changes can be directly detected in the tumor tissue .

Regular participation in external ring tests by the quality initiative Pathology ( QuiP ) and the consistent use of internal controls in all studies ensure a high quality standard of the analyzes performed.
Our portfolio of molecular pathological analyzes constantly evolving and currently consists of the following investigations :

Molecular Pathology
  • Clonality in B-and T -cell lymphoma *
  • Microsatellite instability detection ( MSI) in HNPCC *
  • Mutation Analysis *
    KRAS (Ex. 2-4) , NRAS ( Ex.2 -4) at CRC
    EGFR (Ex. 18 , 19, 20 & 21) in NSCLC
    c-kit (Ex. 9 , 11, 13 & 17) and PDGFRα (Ex. 12, 14 & 18) in GIST
    c-kit (Ex. 9 , 11, 13 & 17) , BRAF (Ex. 15) , NRAS (Ex. 2 & 3) , GNAQ ( Ex.15 ) at MM
    CTNNB1 (Ex. 3) in desmoid tumors
    HFE (Ex. 2 & 4) in hemochromatosis
    Jak2 (Ex. 14) , MPL (Ex. 10) , CALR (Ex. 9) at MPS
  • FISH in lymphoma or leukemia *
    MALT1 in marginal zone lymphoma
    c-myc for Burkitt’s lymphoma
    CCND1 in mantle cell lymphoma
    bcl -2 in follicular lymphoma
    bcr / abl in CML
  • FISH sarcomas *
    EWSR1 in Ewing sarcoma and DSRCT
    SYT1 in synovial sarcoma
    MDM2 in liposarcoma
    FUS in myxoidenLiposarkom and LGFMS
    c -myc amplification in strahlenind . angiosarcoma
    COL1A1 in DFSP
    TFE3 at ASPS
  • FISH in breast and gastric cancer *
    HER2/neu
  • FISH at NCSLC *
    ALK/EML4
  • Fusionsgennachweis from fresh material (RT -PCR) *
    FIP1L1/PDGFRα in HES / CEL
    PML / RAR in AML M3
    BRD4/NUT at NMC
    EWSR1/FLI in Ewing ‘s sarcoma
    PAX3/FKHR & PAX7/FHKR in rhabdomyosarcoma
    AChRα / γ in rhabdomyosarcoma
    EWSR1/ATF1 in clear cell sarcoma
    FUS / CHOP in myxoidenLiposarkom
    SYT1/SSX1 in synovial sarcoma
    EWSR1/WT1 in DSRCT
    FUS/CREB3L1/2 at LGFMS
    COL1A1/PDGFRβ in DFSP
    ASPL/TFE3 at ASPS
  • Pathogen diagnosis *
    EBV ( EBER )
    HPV typing
    Mycobacteria ( M. tuberculosis and atypical M. )